Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: tubulin polymerisation inhibitors - EntreMed

Next Previous
X
Search
Drug Profile

Research programme: tubulin polymerisation inhibitors - EntreMed

Alternative Names: 3,3-Diarylacrylonitriles as tubulin polymerisation inhibitors - EntreMed; CC 4089; CC 5079; ENMD 1420; ENMD 1427; ENMD 1916; Tubulin polymerisation inhibitors - Celgene/EntreMed

Latest Information Update: 04 Dec 2019

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer EntreMed
  • Class Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
  • 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (PO)
  • 09 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top